CRIS
Curis Inc
Halal Rating :
Last Price
$3.38
Last updated:
Market Cap
-
7D Change
0.6%
1 Year Change
-70.19%
Company Overview
Industries
Exchange
Next Earnings Date
Curis, Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. The company's primary focus is on developing small molecule targeted drug candidates for the treatment of various types of cancer. Their lead drug candidate is emavusertib (CA-4948), an IRAK4 kinase inhibitor in development for acute myeloid leukemia and B-cell malignancies.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $2.93m | $13.35m | - | $-150000.0 | 0.00% | 1.12% |
| June 30, 2024 | $2.55m | $15.06m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $2.09m | $14.55m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Curis Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.